CA3050104A1 - Ppary agonist for the treatment of huntington's disease - Google Patents
Ppary agonist for the treatment of huntington's disease Download PDFInfo
- Publication number
- CA3050104A1 CA3050104A1 CA3050104A CA3050104A CA3050104A1 CA 3050104 A1 CA3050104 A1 CA 3050104A1 CA 3050104 A CA3050104 A CA 3050104A CA 3050104 A CA3050104 A CA 3050104A CA 3050104 A1 CA3050104 A1 CA 3050104A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- disease
- huntington
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| US62/447,741 | 2017-01-18 | ||
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3050104A1 true CA3050104A1 (en) | 2018-07-26 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3050104A Abandoned CA3050104A1 (en) | 2017-01-18 | 2018-01-18 | Ppary agonist for the treatment of huntington's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| AU2005295878A1 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| US9028879B2 (en) * | 2009-07-01 | 2015-05-12 | Jds Therapeutics, Llc | Chromium complexes as enhancers of brain glucose transporters |
| WO2015095548A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay huntington's disease progression |
-
2018
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3570841A4 (en) | 2020-08-19 |
| JP2020505448A (ja) | 2020-02-20 |
| BR112019014529A2 (pt) | 2020-02-27 |
| EP3570841A1 (en) | 2019-11-27 |
| KR20190122664A (ko) | 2019-10-30 |
| MX2019008535A (es) | 2019-12-02 |
| SG11201906644YA (en) | 2019-08-27 |
| US20190350918A1 (en) | 2019-11-21 |
| WO2018136635A1 (en) | 2018-07-26 |
| EA201991716A1 (ru) | 2020-02-04 |
| CN110461330A (zh) | 2019-11-15 |
| IL268008A (en) | 2019-09-26 |
| AU2018210165A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6957602B2 (ja) | 神経変性疾患のための治療薬 | |
| CA3079259A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| TW200936127A (en) | Use of cannabinoids in combination with an anti-psychotic medicament | |
| NZ745778A (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| US20100063116A1 (en) | Use of pramipexole or a salt thereof for the treatment of parkinson's disease | |
| HUE024558T2 (hu) | Biotin alkalmazása szklerózis multiplex kezelésére | |
| CN102143687B (zh) | 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 | |
| US10653652B2 (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction | |
| CN112566641A (zh) | 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物 | |
| CN107660147A (zh) | 用于治疗帕金森病和相关障碍的组合物 | |
| Zafonte et al. | Antispasticity medications: uses and limitations of enteral therapy | |
| CN114728012A (zh) | 用于治疗癫痫持续状态的加奈索酮 | |
| Egeberg et al. | Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances | |
| US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| US20190350918A1 (en) | PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE | |
| RU2763425C2 (ru) | Терапевтические агенты для нейродегенеративных заболеваний | |
| JP2002541198A (ja) | 失禁の治療法 | |
| JP2021519349A (ja) | 幻覚とそれに関連する病態の治療のための方法および組成物 | |
| CN110996951A (zh) | 治疗进行性核上性麻痹的PPARγ激动剂 | |
| Ciccone | Geriatric pharmacology | |
| TW202539621A (zh) | 用於治療巴金森氏症的治療劑 | |
| Roller et al. | Parkinsonism and parkinson's disease | |
| RU2849887C2 (ru) | Терапевтические средства против нейродегенеративных заболеваний | |
| CN108025003A (zh) | 前额叶皮质处理病症，步态和肢体障碍治疗 | |
| US20230404955A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere’s disease, tourette’s syndrome, attention deficit hyperactivity disorder and addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240501 |